Cynosure Group LLC Sells 144 Shares of Humana Inc. (NYSE:HUM)

Cynosure Group LLC decreased its position in shares of Humana Inc. (NYSE:HUM) by 10.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,180 shares of the insurance provider’s stock after selling 144 shares during the quarter. Cynosure Group LLC’s holdings in Humana were worth $299,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. FPC Investment Advisory Inc. bought a new position in shares of Humana during the fourth quarter worth $27,000. Centricity Wealth Management LLC bought a new position in Humana during the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA lifted its holdings in Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new position in Humana in the fourth quarter valued at about $33,000. Finally, Atwood & Palmer Inc. increased its holdings in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after acquiring an additional 60 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM opened at $264.67 on Friday. The company has a market cap of $31.94 billion, a PE ratio of 26.60, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The firm has a 50-day moving average of $268.40 and a 200-day moving average of $272.56. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s payout ratio is presently 35.58%.

Analyst Upgrades and Downgrades

HUM has been the subject of several research analyst reports. StockNews.com lowered Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Morgan Stanley lowered their price objective on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Finally, Piper Sandler increased their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Eighteen analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $280.17.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.